Shionogi & Co ( (SGIOF) ) has released its Q4 earnings. Here is a breakdown of the information Shionogi & Co presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Shionogi & Co., Ltd. is a pharmaceutical company based in Tokyo, Japan, known for its focus on research, development, and distribution of prescription drugs, with a significant presence in the global market through innovative treatments and strategic partnerships.
In its latest earnings report for the fiscal year ending March 31, 2025, Shionogi & Co., Ltd. reported a slight increase in revenue by 0.7% to 438.3 billion yen, marking a record high for the third consecutive year. The company also saw a 2.1% rise in operating profit to 156.6 billion yen, attributed to the steady growth in overseas business and increased royalty income.
Key financial highlights include a 5.2% increase in profit attributable to owners of the parent, reaching 170.4 billion yen, and a 21.6% rise in total royalty and dividend income from ViiV to 285 billion yen. The company’s strategic focus on expanding its global footprint was evident in the 18.4% increase in overseas business revenue, driven by strong sales of Cefiderocol in the U.S. and Europe. Additionally, Shionogi made significant investments in research and development, particularly in COVID-19-related projects and other priority areas.
Looking ahead, Shionogi anticipates continued revenue growth, driven by the expansion of its acute respiratory virus infection drugs and new products like QUVIVIQ. The company also plans to increase its R&D spending to accelerate the development of globally marketable growth drivers. Despite the expected rise in expenses, Shionogi forecasts an overall increase in profit, supported by strategic acquisitions and a focus on expanding its market presence.